Atamyo Therapeutics has shared the first clinical results for its ATA-200 gene therapy in LGMD-2C/R5 limb-girdle muscular dystrophy associated with γ-sarcoglycan deficiency (SGCG, gamma-sarcoglycanopathy).  

The results are from a Phase Ib/II clinical trial conducted at the Powell Gene Therapy Center at the University of Florida, supported by The Dion Foundation for Children with Rare Diseases. 

LGMD-2C/R5 is a severe form of muscular dystrophy that appears in childhood and causes loss of walking ability before adulthood, respiratory and heart failure, and premature death.  

The clinical trial is a single-centre study evaluating the safety, pharmacodynamics, efficacy, and immunogenicity of ATA-200 in children aged six to 13 years.  

ATA-200 is an adeno-associated virus (AAV) gene therapy carrying a normal copy of the human SGCG gene and administered as a single intravenous injection at a dose of 1.0E+14 vg/kg.  

The following was observed in the first two patients treated: 

  • More than 90% of muscle fibres expressing the SGCG protein—demonstrating that almost all muscle fibres had received the therapeutic gene (90.2% for patient 1 and 92.1% for patient 2 at six months).  
  • A significant and sustained reduction in CPK levels (a biomarker of muscle damage) and a decrease in transaminases nine months after treatment. 
  • Also nine months post-treatment, clinical benefits were observed on several other important parameters in ambulatory patients, particularly in timed functional tests. 

“These initial results are very encouraging and demonstrate the potential of our product with biological data rarely seen in neuromuscular diseases and at such an early stage of the trial. We are deeply grateful for the collaboration with the Dion Foundation and Dr Barry Byrne of the Powell Gene Therapy Center and proud to offer children with LGMD-R5 the opportunity to receive a treatment that could change their lives,” commented Angela Columbano, CEO, Atamyo Therapeutics.